Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
High Blood Pressure Research Scientific Sessions 2014 Brief Reviews

Gained in Translation

Protective Paradigms for the Poststenotic Kidney

Lilach O. Lerman, Stephen C. Textor
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.114.04364
Hypertension. 2015;65:976-982
Originally published February 23, 2015
Lilach O. Lerman
From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen C. Textor
From the Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Introduction
    • Experimental Models of Renovascular Injury
    • Mechanisms Underlying Poststenotic Kidney Injury
    • Systemic Effects of ARVD
    • Perspectives
    • Sources of Funding
    • Disclosures
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Introduction

Atherosclerotic renovascular disease (ARVD) is more commonly identified than ever before, particularly among the elderly population. By some accounts, >10% of new patients entering dialysis programs in the United States have ARVD as a major contributor to their end-stage renal disease. ARVD is also associated with accelerated renal injury, hypertension, and cardiovascular complications. Renovascular hypertension (RVH) is an independent cardiovascular risk factor and induces greater decline in cardiac function and structure than essential hypertension.1

However, clinical trials show consistently that revascularization of the stenotic renal artery using percutaneous transluminal renal angioplasty (PTRA) results in limited and inconsistent recovery of renal function.2 The reasons for the failure of revascularization to resolve renal dysfunction are complex and may include procedural complications, as well as pre-existing parenchymal injury, including endothelial dysfunction, inflammation, fibrosis, and microvascular remodeling in the poststenotic kidney.3

Atherogenic comorbidities constitute important catalysts of renal damage in ARVD. In fact, atherosclerotic nephropathy can produce renal damage even with hemodynamically insignificant stenoses,4 suggesting a direct effect of atherosclerosis on the kidney. Furthermore, unlike patients with fibromuscular dysplasia, in patients with ARVD a decrease in stenotic-kidney perfusion does not correlate with the angiographic degree of stenosis,5 and cortical perfusion is reduced even with mild stenoses, underscoring the contribution of additional pathogenic factors to renal damage. Therefore, the quest for underlying mechanisms and promising interventions mandates development of experimental platforms that not only involve renal artery stenosis but also emulate the atherosclerotic milieu.

Experimental Models of Renovascular Injury

Useful models of renal artery stenosis have been achieved in many laboratory animal species, including mice, rats, hamsters, rabbits, dogs, and monkeys, but usually without application of comorbidities.6 Our studies focused on developing a swine model with gradually developing renal artery stenosis secondary to unilateral renal arterial implantation of a local irritant coil. The advantages of the pig include its physiology, pathophysiology, vascular lesions, and lipid profile that resemble those observed in humans, and a body size suitable for use of clinical devices and interventions, and in turn rapid clinical translation.7 Pigs with renal artery stenosis are then fed with a high-cholesterol diet8,9 to simulate early diffuse atherosclerosis.

Our studies showed that atherosclerosis superimposed on renal artery stenosis exacerbates renal inflammation, oxidative stress, and fibrosis.8,9 Interestingly, development of RVH was not exacerbated, possibly partly because of increased sodium excretion in hypercholesterolemia.10 Nevertheless, diffuse atherosclerosis aggravated injury in the contralateral kidney11,12 and the heart.13,14 Notably, RVH superimposed on hypercholesterolemia15 or diabetes mellitus16 exacerbates damage in the systemic vasculature and nonstenotic kidney in mice; further studies are needed to determine their impact on the murine stenotic kidney.

Studies using the ARVD swine model aimed to elucidate and target the mechanisms implicated in renal injury in ARVD. In 2-kidneys,1-clip rodents, RVH and renal injury are sustained by interactions among the rennin–angiotensin–aldosterone system, nitric oxide, and vasoconstrictor prostaglandins,17–20 which activate proinflammatory, pro-oxidant, and profibrogenic mechanisms.16,21 In ARVD these mechanisms are compounded by atherogenic factors, which intensify within the poststenotic kidneys, oxidative stress and inflammation22–24 and in turn rarefaction of microvessels.25–27 Loss of microvessels (Figure [A]), a hallmark of many renal diseases, may be driven by fibrosis-restricting expansion of the renal microcirculation,28 by microvascular regression, direct mechanical, or metabolic injury to the microvascular wall, or degradation of growth factors by reactive oxygen species.29,30 Apoptosis and mitochondrial injury also contribute to vascular loss, tubulointerstitial hypoxia, and interstitial fibrosis31,32 leading to renal dysfunction and scarring,27,33–38 the apparent irreversible phase of kidney damage.

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

A, Schematic of injurious mechanisms activated in the poststenotic kidney in atherosclerotic renal artery stenosis (ARAS), and experimental therapeutic interventions that can potentially blunt them. B, Micro–computed tomographic images showing microvascular loss in the poststenotic kidney, which was rescued using mesenchymal stem cell–derived extracellular vesicles (EV).

The failure of renal artery revascularization to restore renal function in ARVD provides the impetus to explore underlying mechanisms and treat the poststenotic kidney directly. Given the postulated paradigm (Figure [B]), we attempted to address mechanisms recognized to induce kidney damage in ARVD.

Mechanisms Underlying Poststenotic Kidney Injury

Hypoxia

The contribution of hypoxia to poststenotic kidney injury has been controversial, partly because early measurements of renal-vein oxygen pressure failed to identify a fall in PO2.39 Nonetheless, studies in a rat 2-kidneys,1-clip model clearly documented renal hypoxia and inefficient oxygen utilization40 linked to increased oxidative stress.41 Indeed, careful studies of renal oxygenation indicate that renal vein PO2 may be deceptive, insofar as it is affected by arteriovenous shunting, countercurrent exchange, and reduced oxygen consumption.42 Subsequently, oxygen probes43 and blood oxygen level–dependent MR have shown that renal hypoxia could be regional, and that significant stenoses induce hypoxia and fibrosis in poststenotic human kidneys.35,44

Nevertheless, restoration of renal arterial patency in ARVD, which aims to alleviate hypoxia, does not necessarily restore stenotic kidney blood flow and function. In pigs with nonatherosclerotic renal artery stenosis, renal function and blood pressure promptly improved after PTRA,3 whereas in pigs with ARVD kidney dysfunction persisted, and correlated with microvascular remodeling,45,46 resembling findings of clinical trials.2 Incomplete recovery of stenotic kidney glomerular filtration rate (GFR) in pigs is linked not only to structural remodeling of the poststenotic kidney but also to preprocedural inflammation and the functionality of renal microvessels.45 Similarly, the poststenotic human kidney releases inflammatory mediators,47 which remain elevated after PTRA despite a fall in renal hypoxia.36 Therefore, although hypoxia characterizes severe renal artery stenosis, it may not be fully responsible for poststenotic kidney dysfunction. This notion may partly account for the inconsistent role of hypoxia in kidney injury in ARVD.

Atherosclerosis

To attenuate atherogenic factors such as hypercholesterolemia, we treated pigs with the cholesterol-lowering drug simvastatin. Simvastatin-treated pigs with renal artery stenosis and normal cholesterol improved stenotic kidney microvascular density and decreased glomerulosclerosis, despite unaltered cholesterol or blood pressure levels.25 Furthermore, in hypercholesterolemic ARVD pigs, despite unchanged RVH or cholesterol levels, simvastatin decreased renal oxidative stress and fibrosis,26 although GFR was unaffected. Hence, although HMG-CoA (3-hydroxy-3-methylglutaryl coenyzme-A) reductase inhibitors have considerable pleiotropic effects on the stenotic kidney, this regimen alone does not suffice to restore renal function.

Activation of the Renin–Angiotensin–Aldosterone System

Blockers of the renin–angiotensin–aldosterone system acutely decrease poststenotic kidney GFR, yet many patients with ARVD tolerate long-term treatment with these agents without difficulty. To explore direct effects of an angiotensin receptor blocker on the poststenotic kidney, pigs with renal artery stenosis were treated with either valsartan or triple therapy (reserpine/hydralazine/hydrochlorothiazide). For a similar decrease in blood pressure, valsartan did not impair GFR more than triple-therapy in this model. Both regimens increased microvessel density, but valsartan also improved poststenotic cortical perfusion and decreased oxidative stress. We interpret these data to indicate that direct beneficial effects of valsartan on the kidney parenchyma may offset its vascular effect to reduce GFR, thereby preserving kidney function.48 Clearly, inhibition of the renin–angiotensin–aldosterone system bestows blood pressure–independent benefits on both the stenotic kidney and the other target organs.

Oxidative and Inflammatory Injury

Angiotensin-II is a potent activator of NAD(P)H oxidase, a major enzymatic source for reactive oxygen species, and other inflammatory and atherogenic mediators increase reactive oxygen species production in the kidney and target organs. In pigs with ARVD, we blunted oxidative stress using a combination of the common antioxidants vitamins E and C.

Antioxidant vitamins had no effect on blood pressure or GFR in pigs with renal artery stenosis, yet decreased renovascular resistance, improved tubular fluid dynamics, and decreased inflammation and fibrosis.49 Similarly, the antioxidant tempol effectively increases cortical blood flow and oxygen tension in clipped kidneys of 2-kidneys,1-clip rats.41 In pigs with ARVD, antioxidant vitamins improved endothelial function50 and upregulated protein degradation systems, resulting in blunted glomerulosclerosis and renal fibrosis, although GFR was not restored in this model. These studies positioned oxidative stress as an important mediator of renal injury in ARVD. The effects of antioxidant are partly mediated by their ability to attenuate renal remodeling because they are more effective in improving renal function and structure when delivered chronically than acutely.51 Antioxidants also restored microvascular architecture in the kidney27 and myocardium52 in renovascular hypertension, but did not fully restore GFR. Negative results of clinical trials also argued against their widespread use. Indeed, in healthy pigs, antioxidant vitamins led to a paradoxical increase in oxidative stress.53 Therefore, alternative strategies are needed to preserve poststenotic kidney function.

Because monocyte chemoattractant protein-1 expression is upregulated in the stenotic kidney in both pigs54 and mice,16,21 we postulated that this inflammatory mediator contributes to poststenotic kidney injury. In pigs, inhibition of monocyte chemoattractant protein-1 with Bindarit has no effect on RVH but improves renal blood flow, GFR, and endothelial function. Tubulointerstitial oxidative stress, inflammation, and fibrosis decreased, although microvascular density increased only slightly.55 Hence, monocyte chemoattractant protein-1 contributes to functional and structural remodeling of the poststenotic kidney and its inhibition may be protective.

Microvascular Rarefaction

Regression and remodeling of intrarenal microvessels are pivotal mechanisms responsible for loss of poststenotic kidney function and progression of chronic kidney disease, and delivery of vascular growth factors improves renal function.56,57 Similarly, antagonism of the endothelin-A receptor enhances microvascular density and renal recovery in pigs with renal artery stenosis,58,59 ascribing an important role to endothelin-1 in regulating the microcirculation in the poststenotic kidney.

Microvascular rarefaction is also amplified by impairment of endogenous repair mechanisms. Circulating endothelial progenitor cells (EPCs) are recruited in response to injury signals to facilitate microvascular and cellular repair, but their number and function can decline in subjects with ARVD after exposure to cardiovascular risk factors. We reasoned that replenishing EPC might enhance repair in poststenotic kidneys.

We isolated from peripheral blood endothelial outgrowth progenitors, which possess proangiogenic characteristics. Injecting these cells directly into the stenotic renal artery increased renal expression of angiogenic factors, enhanced proliferation and maturation of vessels, attenuated microvascular remodeling and fibrosis, and ultimately improved renal blood flow, endothelial function, and GFR.60 EPC delivery also protects the murine kidney subjected to acute ischemic injury.61 Their effectiveness in ARVD is enabled by the expression of cognate receptors corresponding to injury signals released from the stenotic kidney,62 facilitating their local adhesion and retention. Thus, autologous EPCs are effective in both nonatherosclerotic renal artery stenosis and ARVD.

Interestingly, the potency of EPC is greatest at the early phase of renovascular hypertension, corresponding to activation of the renin–angiotensin–aldosterone system.63 Yet, EPCs are less effective in the renal medulla than in the cortex, possibly because few EPCs reach this region. Nonetheless, tubular function was normalized and fibrosis attenuated when EPCs were delivered in association with PTRA.34 Adjunctive EPC delivery during PTRA restored GFR, improved renal blood flow and microvascular density, and decreased prevalence of proinflammatory macrophages and cytokines.64 Therefore, EPCs decrease poststenotic kidney injury and improve revascularization outcomes by preserving microvascular architecture and function and decreasing inflammation and fibrosis. Notably, preservation of renal function in turn improves myocardial microvascular integrity,65 underscoring the important contribution of renal dysfunction from ARVD to its cardiovascular sequelae.

However, EPCs are difficult to harvest from peripheral blood, and their immunogenicity mandates autologous administration. Emerging evidence shows that mesenchymal stem cells (MSC) are accessible for harvesting from many tissue sources, grow robustly in culture, and their anti-inflammatory and immunomodulatory properties render them potentially suitable for allogeneic applications. We found that MSC delivery in conjunction with PTRA in ARVD attenuated interstitial fibrosis, inflammation, microvascular remodeling, oxidative stress, and apoptosis,66 and restored stenotic kidney hemodynamics and function, underscoring their therapeutic potential. Importantly, MSCs are slightly more effective than EPC in restoring renal function, possibly because of greater potency in blunting inflammation and apoptosis.67 MSCs decrease stenotic kidney release of tumor necrosis factor-α and monocyte chemoattractant protein-1,54 consistent with their potent anti-inflammatory properties.

The mechanisms of action of MSC might include regulation of post-transcriptional regulators such as micro-RNAs68 and release of extracellular membrane vesicles.69 Micro-RNA and mRNA packed in these vectors modulate angiogenesis and other pathways in recipient cells and mediate the paracrine activities of MSC (Figure [A]).

Similar to EPCs, MSCs are less effective in repairing medullary damage, possibly because of their relatively lower engraftment rate compared with the cortex (≈1:5). Yet, MSCs adjunctive to PTRA attenuate tubular injury and inflammation and reduce capillary loss.33 Alas, they may paradoxically increase medullary hypoxia by boosting tubular oxygen consumption.33

Mitochondrial Injury

Ischemic kidney injury might be propagated by cell death and disturbed cellular energetics, events that are regulated by mitochondria. Furthermore, ischemia/reperfusion injury may contribute to limited efficacy of renal artery revascularization. To assess the involvement of mitochondria, we infused intravenously a mitochondrial-targeted peptide immediately before and during PTRA. Bendavia is a tetrapeptide that prevents oxidation of cardiolipin, a phospholipid constituent of the inner-mitochondrial membrane. Stenotic kidney blood flow and GFR improved 4 weeks after PTRA with adjunctive Bendavia infusion, compared with pigs undergoing PTRA accompanied by vehicle infusion. Bendavia restored renal mitochondrial biogenesis and decreased microvascular refraction, apoptosis, oxidative stress, and fibrosis.32 Hence, mitochondrial injury incurred during reperfusion may amplify renal injury and limit recovery after PTRA. Importantly, chronic Bendavia treatment without PTRA was also effective in blunting renal damage in ARVD, normalized renal endothelial function, improved kidney oxygenation, and attenuated fibrosis.31 Studies in rats have demonstrated the efficacy of pretreatment with a mitochondrial-targeted peptide to increased renal tolerance to acute ischemia.70 These studies suggest that mitochondrial dysfunction contributes to the pathogenesis of both chronic and acute aspects of kidney injury, and targeting these organelles might protect the ischemic kidney (Figure [B]). Mitochondrial protection also improved cardiac function after reversal of RVH.71,72

Systemic Effects of ARVD

An important observation is that pathways of injury in a stenotic kidney contribute to significant risks for the nonstenotic kidney, the cardiovascular system, and arterial pressure. The poststenotic kidney in both animals and human subjects releases inflammatory injury signals,47,54,65 and their levels rise not only in the stenotic but also in the contralateral kidney, suggesting renorenal crosstalk and systemic effects of ARVD. Consequently, damage and inflammatory markers in the contralateral kidney are greater than those induced by simple nephrectomy or even angiotensin-II infusion.16 Furthermore, cardiac hypertrophy and dysfunction are magnified in patients with RVH compared with essential hypertension.1

Remarkably, the magnitude of RVH seems to be at least partly disassociated from the extent of renal injury. For example, in swine, ARVD-superimposed atherosclerosis magnifies renal injury,8,9 yet RVH levels remain similar to those in pigs with nonatherosclerotic renal artery stenosis.46,73 Furthermore, hypertension can be fully reversed by PTRA despite residual kidney injury,3,45,46,64,66 again suggesting that kidney injury is not closely correlated to the severity of RVH. The disassociation between the reversibility of renal function and hypertension in animal models is consistent with the results of the CORAL trial, in which despite the lack of efficacy of stenting to improve renal function compared with medical therapy alone, it achieved a modest decrease in blood pressure.2

These observations underscore the need for multiple levels of therapy in this disease. Revascularization may have a role specifically related to blood pressure control and avoiding pulmonary edema, whereas adjunctive therapies, directly targeting underlying mechanisms responsible for renal injury in ARVD, are required to recover renal function. Identification of the basic mechanisms that lead to kidney tissue injury in ARVD can assist in the development of targeted therapies. We think that addressing those injurious pathways directly can improve stenotic kidney blood flow, GFR, fibrosis, and reverse microvascular loss. They may also improve the efficacy of revascularization with PTRA and stenting. Such targeted therapeutic interventions with or without PTRA might constitute effective tools for improving kidney and cardiovascular outcomes of ARVD. Importantly, some of the novel experimental approaches seem to also benefit the contralateral kidney and the heart in pigs with ARVD.

Building on observations in animal models, our group has recently moved forward to extend these paradigms into clinical trials for ARVD. We are currently studying the effects of intra-arterial delivery of adipose tissue–derived MSC on tissue oxygenation and inflammatory injury. For patients who are candidates for renal revascularization, phase I trials of intravenous Bendavia will allow direct examination of mitochondrial protection during ischemia/reperfusion processes in the poststenotic kidney during PTRA and stenting. These steps toward clinical translation may assist clinicians in developing strategies to protect and recover function in the poststenotic kidney.

Perspectives

The prevalence of ARVD is on the rise. The failure to demonstrate benefits from renal artery revascularization in prospective clinical trials has led to a precipitous fall in the application of PTRA and stenting, leaving few options available to preserve the poststenotic kidney. Alas, the presence of this kidney, by virtue of low function and robust cytokine production, introduces a significant cardiovascular risk, underscoring the need to identify strategies to attenuate kidney injury and increase the efficacy of interventional techniques. To this end, relevant experimental models are proving invaluable to afford insights into the pathogenesis of ARVD and serve as experimental platforms to test novel therapeutic tools (Figure [B]). Further translational and clinical trials are needed to explore and develop innovative approaches to preserve the poststenotic kidney and improve the management of patients with ARVD.

Sources of Funding

This work was partly supported by National Institutes of Health grants DK73608, DK100081, HL121561, DK104273, and HL123160.

Disclosures

None.

  • Received December 2, 2014.
  • Revision received December 16, 2014.
  • Accepted January 26, 2015.
  • © 2015 American Heart Association, Inc.

References

  1. 1.↵
    1. Khangura KK,
    2. Eirin A,
    3. Kane GC,
    4. Misra S,
    5. Textor SC,
    6. Lerman A,
    7. Lerman LO
    . Cardiac function in renovascular hypertensive patients with and without renal dysfunction. Am J Hypertens. 2014;27:445–453. doi: 10.1093/ajh/hpt203.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Cooper CJ,
    2. Murphy TP,
    3. Cutlip DE,
    4. et al
    ; CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13–22. doi: 10.1056/NEJMoa1310753.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Favreau F,
    2. Zhu XY,
    3. Krier JD,
    4. Lin J,
    5. Warner L,
    6. Textor SC,
    7. Lerman LO
    . Revascularization of swine renal artery stenosis improves renal function but not the changes in vascular structure. Kidney Int. 2010;78:1110–1118. doi: 10.1038/ki.2010.142.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Wright JR,
    2. Shurrab AE,
    3. Cheung C,
    4. Waldek S,
    5. O’Donoghue DJ,
    6. Foley RN,
    7. Mamtora H,
    8. Kalra PA
    . A prospective study of the determinants of renal functional outcome and mortality in atherosclerotic renovascular disease. Am J Kidney Dis. 2002;39:1153–1161. doi: 10.1053/ajkd.2002.33384.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Lerman LO,
    2. Taler SJ,
    3. Textor SC,
    4. Sheedy PF 2nd.,
    5. Stanson AW,
    6. Romero JC
    . Computed tomography-derived intrarenal blood flow in renovascular and essential hypertension. Kidney Int. 1996;49:846–854.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Lerman LO,
    2. Chade AR,
    3. Sica V,
    4. Napoli C
    . Animal models of hypertension: an overview. J Lab Clin Med. 2005;146:160–173. doi: 10.1016/j.lab.2005.05.005.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Lerman LO,
    2. Schwartz RS,
    3. Grande JP,
    4. Sheedy PF,
    5. Romero JC
    . Noninvasive evaluation of a novel swine model of renal artery stenosis. J Am Soc Nephrol. 1999;10:1455–1465.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Chade AR,
    2. Rodriguez-Porcel M,
    3. Grande JP,
    4. Krier JD,
    5. Lerman A,
    6. Romero JC,
    7. Napoli C,
    8. Lerman LO
    . Distinct renal injury in early atherosclerosis and renovascular disease. Circulation. 2002;106:1165–1171.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Chade AR,
    2. Rodriguez-Porcel M,
    3. Grande JP,
    4. Zhu X,
    5. Sica V,
    6. Napoli C,
    7. Sawamura T,
    8. Textor SC,
    9. Lerman A,
    10. Lerman LO
    . Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol. 2003;23:1295–1301. doi: 10.1161/01.ATV.0000077477.40824.52.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Feldstein A,
    2. Krier JD,
    3. Sarafov MH,
    4. Lerman A,
    5. Best PJ,
    6. Wilson SH,
    7. Lerman LO
    . In vivo renal vascular and tubular function in experimental hypercholesterolemia. Hypertension. 1999;34(4 Pt 2):859–864.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Lavi R,
    2. Zhu XY,
    3. Chade AR,
    4. Lin J,
    5. Lerman A,
    6. Lerman LO
    . Simvastatin decreases endothelial progenitor cell apoptosis in the kidney of hypertensive hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol. 2010;30:976–983. doi: 10.1161/ATVBAHA.109.201475.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Rodriguez-Porcel M,
    2. Krier JD,
    3. Lerman A,
    4. Sheedy PF 2nd.,
    5. Romero JC,
    6. Napoli C,
    7. Lerman LO
    . Combination of hypercholesterolemia and hypertension augments renal function abnormalities. Hypertension. 2001;37(2 Pt 2):774–780.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Rodriguez-Porcel M,
    2. Lerman A,
    3. Herrmann J,
    4. Schwartz RS,
    5. Sawamura T,
    6. Condorelli M,
    7. Napoli C,
    8. Lerman LO
    . Hypertension exacerbates the effect of hypercholesterolemia on the myocardial microvasculature. Cardiovasc Res. 2003;58:213–221.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Rodriguez-Porcel M,
    2. Lerman LO,
    3. Herrmann J,
    4. Sawamura T,
    5. Napoli C,
    6. Lerman A
    . Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol. 2003;23:885–891. doi: 10.1161/01.ATV.0000069209.26507.BF.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Arruda RM,
    2. Peotta VA,
    3. Meyrelles SS,
    4. Vasquez EC
    . Evaluation of vascular function in apolipoprotein E knockout mice with angiotensin-dependent renovascular hypertension. Hypertension. 2005;46:932–936. doi: 10.1161/01.HYP.0000182154.61862.52.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Hartono SP,
    2. Knudsen BE,
    3. Lerman LO,
    4. Textor SC,
    5. Grande JP
    . Combined effect of hyperfiltration and renin angiotensin system activation on development of chronic kidney disease in diabetic db/db mice. BMC Nephrol. 2014;15:58. doi: 10.1186/1471-2369-15-58.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Lazartigues E,
    2. Lawrence AJ,
    3. Lamb FS,
    4. Davisson RL
    . Renovascular hypertension in mice with brain-selective overexpression of AT1a receptors is buffered by increased nitric oxide production in the periphery. Circ Res. 2004;95:523–531. doi: 10.1161/01.RES.0000140892.86313.c2.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Cervenka L,
    2. Horácek V,
    3. Vanecková I,
    4. Hubácek JA,
    5. Oliverio MI,
    6. Coffman TM,
    7. Navar LG
    . Essential role of AT1A receptor in the development of 2K1C hypertension. Hypertension. 2002;40:735–741.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Welch WJ,
    2. Patel K,
    3. Modlinger P,
    4. Mendonca M,
    5. Kawada N,
    6. Dennehy K,
    7. Aslam S,
    8. Wilcox CS
    . Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension. Am J Physiol Heart Circ Physiol. 2007;293:H2644–H2649. doi: 10.1152/ajpheart.00748.2007.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Lerman LO,
    2. Nath KA,
    3. Rodriguez-Porcel M,
    4. Krier JD,
    5. Schwartz RS,
    6. Napoli C,
    7. Romero JC
    . Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001;37(2 Pt 2):541–546.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Cheng J,
    2. Zhou W,
    3. Warner GM,
    4. Knudsen BE,
    5. Garovic VD,
    6. Gray CE,
    7. Lerman LO,
    8. Platt JL,
    9. Romero JC,
    10. Textor SC,
    11. Nath KA,
    12. Grande JP
    . Temporal analysis of signaling pathways activated in a murine model of two-kidney, one-clip hypertension. Am J Physiol Renal Physiol. 2009;297:F1055–F1068. doi: 10.1152/ajprenal.90439.2008.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Chade AR,
    2. Bentley MD,
    3. Zhu X,
    4. Rodriguez-Porcel M,
    5. Niemeyer S,
    6. Amores-Arriaga B,
    7. Napoli C,
    8. Ritman EL,
    9. Lerman A,
    10. Lerman LO
    . Antioxidant intervention prevents renal neovascularization in hypercholesterolemic pigs. J Am Soc Nephrol. 2004;15:1816–1825.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Chade AR,
    2. Best PJ,
    3. Rodriguez-Porcel M,
    4. Herrmann J,
    5. Zhu X,
    6. Sawamura T,
    7. Napoli C,
    8. Lerman A,
    9. Lerman LO
    . Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. Kidney Int. 2003;64:962–969. doi: 10.1046/j.1523-1755.2003.00170.x.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Wilson SH,
    2. Chade AR,
    3. Feldstein A,
    4. Sawamura T,
    5. Napoli C,
    6. Lerman A,
    7. Lerman LO
    . Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. Nephrol Dial Transplant. 2003;18:703–709.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Chade AR,
    2. Zhu X,
    3. Mushin OP,
    4. Napoli C,
    5. Lerman A,
    6. Lerman LO
    . Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J. 2006;20:1706–1708. doi: 10.1096/fj.05-5680fje.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Chade AR,
    2. Zhu XY,
    3. Grande JP,
    4. Krier JD,
    5. Lerman A,
    6. Lerman LO
    . Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens. 2008;26:1651–1660. doi: 10.1097/HJH.0b013e328302833a.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Zhu XY,
    2. Chade AR,
    3. Rodriguez-Porcel M,
    4. Bentley MD,
    5. Ritman EL,
    6. Lerman A,
    7. Lerman LO
    . Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol. 2004;24:1854–1859. doi: 10.1161/01.ATV.0000142443.52606.81.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Chade AR,
    2. Mushin OP,
    3. Zhu X,
    4. Rodriguez-Porcel M,
    5. Grande JP,
    6. Textor SC,
    7. Lerman A,
    8. Lerman LO
    . Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension. 2005;46:772–779. doi: 10.1161/01.HYP.0000184250.37607.da.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Lerman LO,
    2. Chade AR
    . Atherosclerotic process, renovascular disease and outcomes from bench to bedside. Curr Opin Nephrol Hypertens. 2006;15:583–587. doi: 10.1097/01.mnh.0000247494.77752.f4.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Lerman LO,
    2. Chade AR
    . Angiogenesis in the kidney: a new therapeutic target? Curr Opin Nephrol Hypertens. 2009;18:160–165. doi: 10.1097/MNH.0b013e32831ec1db.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Eirin A,
    2. Ebrahimi B,
    3. Zhang X,
    4. Zhu XY,
    5. Woollard JR,
    6. He Q,
    7. Textor SC,
    8. Lerman A,
    9. Lerman LO
    . Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res. 2014;103:461–472. doi: 10.1093/cvr/cvu157.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Eirin A,
    2. Li Z,
    3. Zhang X,
    4. Krier JD,
    5. Woollard JR,
    6. Zhu XY,
    7. Tang H,
    8. Herrmann SM,
    9. Lerman A,
    10. Textor SC,
    11. Lerman LO
    . A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis. Hypertension. 2012;60:1242–1249. doi: 10.1161/HYPERTENSIONAHA.112.199919.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Ebrahimi B,
    2. Eirin A,
    3. Li Z,
    4. Zhu XY,
    5. Zhang X,
    6. Lerman A,
    7. Textor SC,
    8. Lerman LO
    . Mesenchymal stem cells improve medullary inflammation and fibrosis after revascularization of swine atherosclerotic renal artery stenosis. PLoS One. 2013;8:e67474. doi: 10.1371/journal.pone.0067474.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Ebrahimi B,
    2. Li Z,
    3. Eirin A,
    4. Zhu XY,
    5. Textor SC,
    6. Lerman LO
    . Addition of endothelial progenitor cells to renal revascularization restores medullary tubular oxygen consumption in swine renal artery stenosis. Am J Physiol Renal Physiol. 2012;302:F1478–F1485. doi: 10.1152/ajprenal.00563.2011.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Gloviczki ML,
    2. Glockner JF,
    3. Crane JA,
    4. McKusick MA,
    5. Misra S,
    6. Grande JP,
    7. Lerman LO,
    8. Textor SC
    . Blood oxygen level-dependent magnetic resonance imaging identifies cortical hypoxia in severe renovascular disease. Hypertension. 2011;58:1066–1072. doi: 10.1161/HYPERTENSIONAHA.111.171405.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Saad A,
    2. Herrmann SM,
    3. Crane J,
    4. Glockner JF,
    5. McKusick MA,
    6. Misra S,
    7. Eirin A,
    8. Ebrahimi B,
    9. Lerman LO,
    10. Textor SC
    . Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate. Circ Cardiovasc Interv. 2013;6:428–435. doi: 10.1161/CIRCINTERVENTIONS.113.000219.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Textor SC,
    2. Gloviczki ML,
    3. Flessner MF,
    4. Calhoun DA,
    5. Glockner J,
    6. Grande JP,
    7. McKusick MA,
    8. Cha SS,
    9. Lerman LO
    . Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites. Am J Kidney Dis. 2012;59:229–237. doi: 10.1053/j.ajkd.2011.09.023.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Zhu XY,
    2. Daghini E,
    3. Chade AR,
    4. Lavi R,
    5. Napoli C,
    6. Lerman A,
    7. Lerman LO
    . Disparate effects of simvastatin on angiogenesis during hypoxia and inflammation. Life Sci. 2008;83:801–809. doi: 10.1016/j.lfs.2008.09.029.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Gloviczki ML,
    2. Glockner JF,
    3. Lerman LO,
    4. McKusick MA,
    5. Misra S,
    6. Grande JP,
    7. Textor SC
    . Preserved oxygenation despite reduced blood flow in poststenotic kidneys in human atherosclerotic renal artery stenosis. Hypertension. 2010;55:961–966. doi: 10.1161/HYPERTENSIONAHA.109.145227.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Welch WJ,
    2. Mendonca M,
    3. Aslam S,
    4. Wilcox CS
    . Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the postclipped 2K,1C kidney. Hypertension. 2003;41(3 Pt 2):692–696. doi: 10.1161/01.HYP.0000052945.84627.8F.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Palm F,
    2. Onozato M,
    3. Welch WJ,
    4. Wilcox CS
    . Blood pressure, blood flow, and oxygenation in the clipped kidney of chronic 2-kidney, 1-clip rats: effects of tempol and Angiotensin blockade. Hypertension. 2010;55:298–304. doi: 10.1161/HYPERTENSIONAHA.109.135426.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Evans RG,
    2. O’Connor PM
    . Initiation and progression of chronic kidney disease: can we definitively test the chronic hypoxia hypothesis? Hypertension. 2013;62:827–828. doi: 10.1161/HYPERTENSIONAHA.113.02047.
    OpenUrlFREE Full Text
  43. 43.↵
    1. Warner L,
    2. Gomez SI,
    3. Bolterman R,
    4. Haas JA,
    5. Bentley MD,
    6. Lerman LO,
    7. Romero JC
    . Regional decreases in renal oxygenation during graded acute renal arterial stenosis: a case for renal ischemia. Am J Physiol Regul Integr Comp Physiol. 2009;296:R67–R71. doi: 10.1152/ajpregu.90677.2008.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Gloviczki ML,
    2. Keddis MT,
    3. Garovic VD,
    4. Friedman H,
    5. Herrmann S,
    6. McKusick MA,
    7. Misra S,
    8. Grande JP,
    9. Lerman LO,
    10. Textor SC
    . TGF expression and macrophage accumulation in atherosclerotic renal artery stenosis. Clin J Am Soc Nephrol. 2013;8:546–553. doi: 10.2215/CJN.06460612.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Eirin A,
    2. Ebrahimi B,
    3. Zhang X,
    4. Zhu XY,
    5. Tang H,
    6. Crane JA,
    7. Lerman A,
    8. Textor SC,
    9. Lerman LO
    . Changes in glomerular filtration rate after renal revascularization correlate with microvascular hemodynamics and inflammation in Swine renal artery stenosis. Circ Cardiovasc Interv. 2012;5:720–728. doi: 10.1161/CIRCINTERVENTIONS.112.972596.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Eirin A,
    2. Zhu XY,
    3. Urbieta-Caceres VH,
    4. Grande JP,
    5. Lerman A,
    6. Textor SC,
    7. Lerman LO
    . Persistent kidney dysfunction in swine renal artery stenosis correlates with outer cortical microvascular remodeling. Am J Physiol Renal Physiol. 2011;300:F1394–F1401. doi: 10.1152/ajprenal.00697.2010.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Eirin A,
    2. Gloviczki ML,
    3. Tang H,
    4. Gössl M,
    5. Jordan KL,
    6. Woollard JR,
    7. Lerman A,
    8. Grande JP,
    9. Textor SC,
    10. Lerman LO
    . Inflammatory and injury signals released from the post-stenotic human kidney. Eur Heart J. 2013;34:540–548a. doi: 10.1093/eurheartj/ehs197.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Zhang X,
    2. Eirin A,
    3. Li ZL,
    4. Crane JA,
    5. Krier JD,
    6. Ebrahimi B,
    7. Pawar AS,
    8. Zhu XY,
    9. Tang H,
    10. Jordan KL,
    11. Lerman A,
    12. Textor SC,
    13. Lerman LO
    . Angiotensin receptor blockade has protective effects on the poststenotic porcine kidney. Kidney Int. 2013;84:767–775. doi: 10.1038/ki.2013.144.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Chade AR,
    2. Rodriguez-Porcel M,
    3. Herrmann J,
    4. Krier JD,
    5. Zhu X,
    6. Lerman A,
    7. Lerman LO
    . Beneficial effects of antioxidant vitamins on the stenotic kidney. Hypertension. 2003;42:605–612. doi: 10.1161/01.HYP.0000089880.32275.7C.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Chade AR,
    2. Rodriguez-Porcel M,
    3. Herrmann J,
    4. Zhu X,
    5. Grande JP,
    6. Napoli C,
    7. Lerman A,
    8. Lerman LO
    . Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol. 2004;15:958–966.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Chade AR,
    2. Krier JD,
    3. Rodriguez-Porcel M,
    4. Breen JF,
    5. McKusick MA,
    6. Lerman A,
    7. Lerman LO
    . Comparison of acute and chronic antioxidant interventions in experimental renovascular disease. Am J Physiol Renal Physiol. 2004;286:F1079–F1086. doi: 10.1152/ajprenal.00385.2003.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Rodriguez-Porcel M,
    2. Herrman J,
    3. Chade AR,
    4. Krier JD,
    5. Breen JF,
    6. Lerman A,
    7. Lerman LO
    . Long-term antioxidant intervention improves myocardial microvascular function in experimental hypertension. Hypertension. 2004;43:493–498. doi: 10.1161/01.HYP.0000111834.03000.e4.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Daghini E,
    2. Zhu XY,
    3. Versari D,
    4. Bentley MD,
    5. Napoli C,
    6. Lerman A,
    7. Lerman LO
    . Antioxidant vitamins induce angiogenesis in the normal pig kidney. Am J Physiol Renal Physiol. 2007;293:F371–F381. doi: 10.1152/ajprenal.00475.2006.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Eirin A,
    2. Zhang X,
    3. Zhu XY,
    4. Tang H,
    5. Jordan KL,
    6. Grande JP,
    7. Dietz AB,
    8. Lerman A,
    9. Textor SC,
    10. Lerman LO
    . Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis. Nephrol Dial Transplant. 2014;29:274–282. doi: 10.1093/ndt/gft305.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Zhu XY,
    2. Chade AR,
    3. Krier JD,
    4. Daghini E,
    5. Lavi R,
    6. Guglielmotti A,
    7. Lerman A,
    8. Lerman LO
    . The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens. 2009;27:2063–2073. doi: 10.1097/HJH.0b013e3283300192.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Stewart N,
    2. Chade AR
    . Renoprotective effects of hepatocyte growth factor in the stenotic kidney. Am J Physiol Renal Physiol. 2013;304:F625–F633. doi: 10.1152/ajprenal.00504.2012.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Chade AR,
    2. Kelsen S
    . Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: a novel potential therapeutic approach. Am J Physiol Renal Physiol. 2012;302:F1342–F1350. doi: 10.1152/ajprenal.00674.2011.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Chade AR,
    2. Stewart NJ,
    3. Peavy PR
    . Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease. Kidney Int. 2014;85:833–844. doi: 10.1038/ki.2013.477.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Chade AR,
    2. Tullos N,
    3. Stewart NJ,
    4. Surles B
    . Endothelin-a Receptor Antagonism after Renal Angioplasty Enhances Renal Recovery in Renovascular Disease. J Am Soc Nephrol. 2014:10.1681/ASN.2014040323.
  60. 60.↵
    1. Chade AR,
    2. Zhu X,
    3. Lavi R,
    4. Krier JD,
    5. Pislaru S,
    6. Simari RD,
    7. Napoli C,
    8. Lerman A,
    9. Lerman LO
    . Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation. 2009;119:547–557. doi: 10.1161/CIRCULATIONAHA.108.788653.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Patschan D,
    2. Krupincza K,
    3. Patschan S,
    4. Zhang Z,
    5. Hamby C,
    6. Goligorsky MS
    . Dynamics of mobilization and homing of endothelial progenitor cells after acute renal ischemia: modulation by ischemic preconditioning. Am J Physiol Renal Physiol. 2006;291:F176–F185. doi: 10.1152/ajprenal.00454.2005.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Chade AR,
    2. Zhu XY,
    3. Krier JD,
    4. Jordan KL,
    5. Textor SC,
    6. Grande JP,
    7. Lerman A,
    8. Lerman LO
    . Endothelial progenitor cells homing and renal repair in experimental renovascular disease. Stem Cells. 2010;28:1039–1047. doi: 10.1002/stem.426.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Zhu XY,
    2. Urbieta Caceres VH,
    3. Favreau FD,
    4. Krier JD,
    5. Lerman A,
    6. Lerman LO
    . Enhanced endothelial progenitor cell angiogenic potency, present in early experimental renovascular hypertension, deteriorates with disease duration. J Hypertens. 2011;29:1972–1979. doi: 10.1097/HJH.0b013e32834ae611.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Eirin A,
    2. Zhu XY,
    3. Li Z,
    4. Ebrahimi B,
    5. Zhang X,
    6. Tang H,
    7. Korsmo MJ,
    8. Chade AR,
    9. Grande JP,
    10. Ward CJ,
    11. Simari RD,
    12. Lerman A,
    13. Textor SC,
    14. Lerman LO
    . Endothelial outgrowth cells shift macrophage phenotype and improve kidney viability in swine renal artery stenosis. Arterioscler Thromb Vasc Biol. 2013;33:1006–1013. doi: 10.1161/ATVBAHA.113.301164.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Urbieta-Caceres VH,
    2. Zhu XY,
    3. Jordan KL,
    4. Tang H,
    5. Textor K,
    6. Lerman A,
    7. Lerman LO
    . Selective improvement in renal function preserved remote myocardial microvascular integrity and architecture in experimental renovascular disease. Atherosclerosis. 2012;221:350–358. doi: 10.1016/j.atherosclerosis.2011.10.005.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Eirin A,
    2. Zhu XY,
    3. Krier JD,
    4. Tang H,
    5. Jordan KL,
    6. Grande JP,
    7. Lerman A,
    8. Textor SC,
    9. Lerman LO
    . Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells. 2012;30:1030–1041. doi: 10.1002/stem.1047.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Zhu XY,
    2. Urbieta-Caceres V,
    3. Krier JD,
    4. Textor SC,
    5. Lerman A,
    6. Lerman LO
    . Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms. Stem Cells. 2013;31:117–125. doi: 10.1002/stem.1263.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Zhu XY,
    2. Ebrahimi B,
    3. Eirin A,
    4. Woollard JR,
    5. Tang H,
    6. Jordan KL,
    7. Ofori M,
    8. Saad A,
    9. Herrmann SM,
    10. Dietz AB,
    11. Textor SC,
    12. Lerman A,
    13. Lerman LO
    . Renal vein levels of microRNA-26a are lower in the poststenotic kidney. J Am Soc Nephrol. In press.
  69. 69.↵
    1. Eirin A,
    2. Riester SM,
    3. Zhu XY,
    4. Tang H,
    5. Evans JM,
    6. O’Brien D,
    7. van Wijnen AJ,
    8. Lerman LO
    . MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells. Gene. 2014;551:55–64. doi: 10.1016/j.gene.2014.08.041.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Szeto HH,
    2. Liu S,
    3. Soong Y,
    4. Birk AV
    . Improving mitochondrial bioenergetics under ischemic conditions increases warm ischemia tolerance in the kidney. Am J Physiol Renal Physiol. 2015;308:F11–F21. doi: 10.1152/ajprenal.00366.2014.
    OpenUrlAbstract/FREE Full Text
  71. 71.↵
    1. Eirin A,
    2. Williams BJ,
    3. Ebrahimi B,
    4. Zhang X,
    5. Crane JA,
    6. Lerman A,
    7. Textor SC,
    8. Lerman LO
    . Mitochondrial targeted peptides attenuate residual myocardial damage after reversal of experimental renovascular hypertension. J Hypertens. 2014;32:154–165. doi: 10.1097/HJH.0b013e3283658a53.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Eirin A,
    2. Lerman A,
    3. Lerman LO
    . Mitochondrial injury and dysfunction in hypertension-induced cardiac damage. Eur Heart J. 2014;35:3258–3266. doi: 10.1093/eurheartj/ehu436.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Urbieta-Caceres VH,
    2. Lavi R,
    3. Zhu XY,
    4. Crane JA,
    5. Textor SC,
    6. Lerman A,
    7. Lerman LO
    . Early atherosclerosis aggravates the effect of renal artery stenosis on the swine kidney. Am J Physiol Renal Physiol. 2010;299:F135–F140. doi: 10.1152/ajprenal.00159.2010.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
May 2015, Volume 65, Issue 5
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Introduction
    • Experimental Models of Renovascular Injury
    • Mechanisms Underlying Poststenotic Kidney Injury
    • Systemic Effects of ARVD
    • Perspectives
    • Sources of Funding
    • Disclosures
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Gained in Translation
    Lilach O. Lerman and Stephen C. Textor
    Hypertension. 2015;65:976-982, originally published February 23, 2015
    https://doi.org/10.1161/HYPERTENSIONAHA.114.04364

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Gained in Translation
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Gained in Translation
    Lilach O. Lerman and Stephen C. Textor
    Hypertension. 2015;65:976-982, originally published February 23, 2015
    https://doi.org/10.1161/HYPERTENSIONAHA.114.04364
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured